BioCentury
ARTICLE | Clinical News

Cavatak: Interim Phase I/II data

May 4, 2015 7:00 AM UTC

Interim data from 6 patients with advanced cancer in the open-label, dose-escalation, U.K. Phase I/II STORM trial showed that multiple doses of IV Cavatak were generally well tolerated with no treatme...